← back to search

Ricardo Sobhie Diaz

Universidade de São Paulo · BR
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, and Hepatitis C virus research.
h-index
40
citations
5,467
works
257
NIH funding
primary concept
Medicine
email

Recent publications

Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios
Viruses 2026cited by 0position: contributordoi
Multiple Infections, Recombination, and Hypermutation During a 12-Month Prospective Study of Five HIV-1 Infected Individuals
Microbiology Research 2026cited by 0position: contributordoi
A national cross-sectional analysis of surveillance drug resistance mutations among recently diagnosed antiretroviral naïve Brazilian people with HIV
The Lancet Regional Health - Americas 2025cited by 2position: contributordoi
Comparison of the Performance of Commercially Available Quantitative Viral Load Assays Using Clinical Samples from Patients from Regions Where Distinct HIV-1 Subtypes Co-Circulate: Potential Implications for Patient Management.
2025cited by 0position: contributordoi
Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV.
2025cited by 0position: contributordoi
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
New England Journal of Medicine 2024cited by 206position: middledoi
Cardiometabolic health in people with HIV: expert consensus review.
2024cited by 14position: contributordoi
T cell-mediated Immune response and correlates of inflammation and their relationship with COVID-19 clinical severity: not an intuitive guess.
2024cited by 5position: contributordoi
Genetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection.
2024cited by 1position: contributordoi
People living with HIV co-infected with the Kaposi Sarcoma-associated Herpes Virus have a distinct HIV Tat profile and higher rates of antiretroviral virologic failure, more evident among those with Kaposi's sarcoma.
2024cited by 0position: contributordoi
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil.
2023cited by 22position: contributordoi
Could well-established, widely available, and simple laboratory techniques explain a laboratory origin of SARS-CoV-2?
2023cited by 0position: contributordoi
Chlamydia trachomatis, Neisseria gonorrhoeae and human papillomavirus infections of lower genital tract of Indigenous women from Xingu Indigenous Park.
2023cited by 0position: contributordoi
Reducing the Immunogenicity of Pulchellin A-Chain, Ribosome-Inactivating Protein Type 2, by Computational Protein Engineering for Potential New Immunotoxins
J 2023cited by 0position: contributordoi
People living with HIV co-infected with the Kaposi sarcoma-associated Herpes Virus have a distinct HIV Tat profile and higher rates of antiretroviral virologic failure, more evident among those with Kaposi's sarcoma.
2023cited by 0position: contributordoi
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
2022cited by 172position: contributordoi
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.
2022cited by 55position: contributordoi
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication <i>In Vitro</i> and Decreases Viral Titers and Disease Progression in Syrian Hamsters
mBio 2022cited by 41position: middledoi
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication <i>In Vitro</i> and Decreases Viral Titers and Disease Progression in Syrian Hamsters.
2022cited by 36position: contributordoi
Environmental Changes and the Impact on the Human Infections by Dengue, Chikungunya and Zika Viruses in Northern Brazil, 2010-2019.
2022cited by 17position: contributordoi
Re-emergence of mayaro virus and coinfection with chikungunya during an outbreak in the state of Tocantins/Brazil.
2022cited by 16position: contributordoi
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
2022cited by 14position: contributordoi
Study of Viral Photoinactivation by UV-C Light and Photosensitizer Using a Pseudotyped Model.
2022cited by 8position: contributordoi
Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial.
2022cited by 7position: contributordoi
Effects of Carbon Nanomaterials and <i>Aloe vera</i> on Melanomas-Where Are We? Recent Updates.
2022cited by 6position: contributordoi
Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities.
2022cited by 5position: contributordoi
3D Bioprinted Neural-Like Tissue as a Platform to Study Neurotropism of Mouse-Adapted SARS-CoV-2.
2022cited by 5position: contributordoi
Antiretroviral Drug-Resistance Mutations on the <i>Gag</i> Gene: Mutation Dynamics during Analytic Treatment Interruption among Individuals Experiencing Virologic Failure.
2022cited by 2position: contributordoi
Pre-Exposure Prophylaxis Failure With a Multiple Drug-Resistant HIV-1 Clade C Virus in Brazil.
2022cited by 0position: contributordoi
Detection of human feces pecovirus in newly diagnosed HIV patients in Brazil.
2022cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 27 papers (2019–2026)James R Hunter · Universidade Federal de São Paulo7 papers (2020–2025)Santiago Moreno · Universidad del Rosario2 papers (2020–2020)Elidamar Nunes de Carvalho Lima · Instituto Butantan2 papers (2022–2022)Luiz Mario Janini · Universidade Federal do Rio de Janeiro2 papers (2022–2026)Mohammad Sadraeian · Montana State University2 papers (2021–2023)Iart Luca Shytaj · University of Bristol2 papers (2022–2025)José Roberto Castilho Piqueira · Universidade de São Paulo2 papers (2022–2022)Reinaldo Salomão · Universidade Federal de São Paulo2 papers (2019–2022)Antonella Castagna · University of Rome Tor Vergata2 papers (2020–2020)Hsin‐Yao Tang · The Wistar Institute2 papers (2021–2021)Estebán Martínez · Real Academia Española1 papers (2024–2024)MohamedHusen Munshi · Center for Cancer Research1 papers (2021–2021)Olivier Lambotte · Université Paris Cité1 papers (2021–2021) · 1 papers (2015–2015) · 1 papers (2015–2015)Bojana Lucic · Heidelberg University1 papers (2021–2021)Francesco A. Procopio · University of Lausanne1 papers (2021–2021)Sheetal Sreeram · Case Western Reserve University1 papers (2021–2021)Niki Georgiou · Utrecht University1 papers (2013–2013)